News

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...
Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...
A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...
GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...
Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to know before stopping.
(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...
GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...
The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...
People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...
Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...
The team found that the tirzepatide-treated mice lost about 20 percent of their body weight, mostly from reduced fat mass. In ...
Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.